Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha: a key factor in autoimmune disease?

Jarka Plskova1, Kathrin Greiner, Elizabeth Muckersie

  • 1Department of Ophthalmology, University of Aberdeen, Aberdeen, Scotland, United Kingdom.

Investigative Ophthalmology & Visual Science
|August 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myeloid Cell Protein Tyrosine Phosphatase 1B Drives Retinal Neurodegeneration in Diabetic Mice.

Diabetes·2026
Same author

Infection control in the brain and the eye.

Acta ophthalmologica·2026
Same author

Antigen-specific polyfunctional cytotoxic T cells differentiate intraocular from peripheral blood immune responses in posterior uveitis.

Clinical & translational immunology·2025
Same author

Protocol for isolating and characterizing human vitreous immune cell infiltrates by flow cytometry and single-cell transcriptomic studies.

STAR protocols·2025
Same author

Evolution of the ocular immune system.

Eye (London, England)·2024
Same author

Immune Privilege Furnishes a Niche for Latent Infection.

Frontiers in ophthalmology·2024

Interferon-alpha effectively treats uveitis by boosting IL-10 producing T-cells. This suggests a potential mechanism for controlling inflammation in Behçet's disease patients with impaired IFN-alpha production.

Area of Science:

  • Immunology
  • Ophthalmology
  • Rheumatology

Background:

  • Behçet's disease is an inflammatory condition that can cause uveitis, a sight-threatening eye inflammation.
  • Interferon-alpha (IFN-alpha) is an established treatment for uveitis in Behçet's disease.

Purpose of the Study:

  • To elucidate the mechanism of action of IFN-alpha in treating noninfectious sight-threatening uveitis.
  • To investigate the impact of IFN-alpha on immune cell populations and function in uveitis patients.

Main Methods:

  • Assessed circulating plasmacytoid dendritic cells (pDCs) and their IFN-alpha production capacity in patients with refractory uveitis and healthy controls.
  • Analyzed peripheral blood CD4+ T-cell phenotype, activation status, chemokine receptor expression, and intracellular cytokine production via flow cytometry before and after IFN-alpha treatment.

Related Experiment Videos

Main Results:

  • IFN-alpha treatment led to positive clinical responses in all uveitis patients.
  • Patients' pDCs showed a reduced capacity to produce IFN-alpha in response to CpG stimulation.
  • IFN-alpha therapy increased IL-10 production in T-cells and altered T-cell activation markers and chemokine receptor expression.

Conclusions:

  • IFN-alpha may exert its therapeutic effect by inducing IL-10-producing T-cells, potentially T-regulatory cells.
  • A defect in pDC-derived IFN-alpha production might contribute to T-cell dysregulation in uveitis.
  • Exogenous IFN-alpha administration can potentially overcome this defect and manage uveitis.